Macrocorticotropinoma shrinkage and control of hypercortisolism under long-term cabergoline therapy: case report
- 22 October 2011
- journal article
- case report
- Published by Springer Nature in Pituitary
- Vol. 15 (1) , 33-36
Abstract
Cushing’s disease is the result of chronic overproduction of ACTH by a pituitary tumor. Although the optimal treatment is surgical removal of the adenoma, medical treatment might be an option in selected cases. A 40-year old woman with Cushing’s disease was treated with cabergoline, a neuromodulatory drug, for a corticotrophic macroadenoma. Treatment was initiated at a weekly dose of 0.5 mg and then, on the basis of the evolution of UFC values, adjusted until it reached 6 mg/week. With cabergoline treatment the patient was asymptomatic, the pituitary adenoma showed a significant shrinkage on MRI and urinary cortisol excretion remained within the normal range during 7 years. We show the effectiveness of cabergoline in maintaining long-term biochemical control of hypercortisolism with significant reduction and stabilization of macroadenoma volume in a patient with Cushing’s disease.Keywords
This publication has 14 references indexed in Scilit:
- Cabergoline monotherapy in the long-term treatment of Cushing's diseaseEuropean Journal of Endocrinology, 2010
- Long-Term Management with Octreotide or Cabergoline in Ectopic Corticotropin Hypersecretion: Case Report and Literature ReviewEndocrine Practice, 2010
- Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing’s diseasePituitary, 2009
- The Medical Treatment of Cushing’s Disease: Effectiveness of Chronic Treatment with the Dopamine Agonist Cabergoline in Patients Unsuccessfully Treated by SurgeryThe Journal of Clinical Endocrinology & Metabolism, 2009
- Treatment of Adrenocorticotropin-Dependent Cushing’s Syndrome: A Consensus StatementThe Journal of Clinical Endocrinology & Metabolism, 2008
- Dopamine Receptor Expression and Function in Human Normal Adrenal Gland and Adrenal TumorsThe Journal of Clinical Endocrinology & Metabolism, 2004
- Complete remission of Nelson’s syndrome after 1-year treatment with cabergolineJournal of Endocrinological Investigation, 1999
- Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 PatientsThe Journal of Clinical Endocrinology & Metabolism, 1999
- Cabergoline in the Treatment of Acromegaly: A Study in 64 PatientsThe Journal of Clinical Endocrinology & Metabolism, 1998
- Cabergoline in the Treatment of Acromegaly: A Study in 64 PatientsThe Journal of Clinical Endocrinology & Metabolism, 1998